BIO-TECHNE Corp Financial Summary

Quick Answer

BIO-TECHNE Corp reported Total Revenue of $1.22 billion for fiscal year 2025.

BIO-TECHNE Corp — Key Financials by Year

Metric 2025 2024 2023 2022 2021 2020
Total Revenue $1.22B
+5.2%
$1.16B
+2.0%
$1.14B
+2.8%
$1.11B
+18.7%
$931.03M
+26.0%
$738.69M
+3.5%
Revenue (ASC 606) $1.22B
+5.2%
$1.16B
+2.0%
$1.14B
+2.8%
$1.11B
+18.7%
$931.03M
+26.0%
$738.69M
+3.5%
Net Income $73.40M
-56.3%
$168.10M
-41.1%
$285.26M
+4.9%
$272.05M
+93.8%
$140.41M
-38.8%
$229.30M
+138.7%
Diluted EPS $0.46
-56.2%
$1.05
-40.3%
$1.76
+6.0%
$1.66
+90.8%
$0.87
-85.1%
$5.82
+135.6%
Total Assets $2.56B
-5.4%
$2.70B
+2.5%
$2.64B
+15.0%
$2.29B
+1.4%
$2.26B
+11.6%
$2.03B
+7.6%
Cash and Equivalents $162.19M
+6.8%
$151.79M
-15.9%
$180.57M
+4.6%
$172.57M
-13.3%
$199.09M
+35.8%
$146.62M
+45.3%
Stockholders Equity $1.92B
-7.3%
$2.07B
+5.2%
$1.97B
+15.6%
$1.70B
+8.9%
$1.56B
+13.2%
$1.38B
+18.5%
Operating Income $102.25M
-50.5%
$206.69M
-30.9%
$298.94M
+0.8%
$296.59M
+25.0%
$237.30M
+50.7%
$157.42M
+7.3%
Gross Profit $790.27M
+2.7%
$769.73M
-0.0%
$769.82M
+1.8%
$756.50M
+19.5%
$632.85M
+31.0%
$483.19M
+2.0%
Shares Outstanding 154.97M
-2.1%
158.22M
+0.4%
157.64M
+0.6%
156.64M
+302.1%
38.96M
+1.3%
38.45M
+1.4%

Most Recent Quarter

Metric Quarter Ending Value YoY QoQ
Total Revenue December 31, 2025 $295.88M -0.4% +3.3%
Revenue (ASC 606) December 31, 2025 $295.88M -0.4% +3.3%
Net Income December 31, 2025 $38.01M +8.9% -0.5%
Diluted EPS December 31, 2025 $0.24 +9.1% +0.0%
Total Assets December 31, 2025 $2.52B -5.5% -0.1%
Cash and Equivalents December 31, 2025 $172.88M -2.6% +19.3%
Stockholders Equity December 31, 2025 $2.01B -3.2% +2.3%
Operating Income December 31, 2025 $54.46M +14.9% +14.3%
Gross Profit December 31, 2025 $191.28M -1.3% +1.7%
Shares Outstanding December 31, 2025 155.88M -1.3% +0.1%
  • BIO-TECHNE Corp reported Total Revenue of $1.22 billion for fiscal year 2025.
  • BIO-TECHNE Corp showed an increase of +5.2% in Total Revenue compared to the prior fiscal year.
  • BIO-TECHNE Corp reported Revenue (ASC 606) of $1.22 billion for fiscal year 2025.
  • BIO-TECHNE Corp showed an increase of +5.2% in Revenue (ASC 606) compared to the prior fiscal year.
  • BIO-TECHNE Corp reported Net Income of $73.40 million for fiscal year 2025.
  • BIO-TECHNE Corp showed a decrease of -56.3% in Net Income compared to the prior fiscal year.
  • BIO-TECHNE Corp reported Diluted EPS of $0.46 per share for fiscal year 2025.
  • BIO-TECHNE Corp showed a decrease of -56.2% in Diluted EPS compared to the prior fiscal year.
  • BIO-TECHNE Corp reported Total Assets of $2.56 billion for fiscal year 2025.
  • BIO-TECHNE Corp showed a decrease of -5.4% in Total Assets compared to the prior fiscal year.
  • BIO-TECHNE Corp reported Cash and Equivalents of $162.19 million for fiscal year 2025.
  • BIO-TECHNE Corp showed an increase of +6.8% in Cash and Equivalents compared to the prior fiscal year.
  • BIO-TECHNE Corp reported Stockholders Equity of $1.92 billion for fiscal year 2025.
  • BIO-TECHNE Corp showed a decrease of -7.3% in Stockholders Equity compared to the prior fiscal year.
  • BIO-TECHNE Corp reported Operating Income of $102.25 million for fiscal year 2025.
  • BIO-TECHNE Corp showed a decrease of -50.5% in Operating Income compared to the prior fiscal year.
  • BIO-TECHNE Corp reported Gross Profit of $790.27 million for fiscal year 2025.
  • BIO-TECHNE Corp showed an increase of +2.7% in Gross Profit compared to the prior fiscal year.
  • BIO-TECHNE Corp reported Shares Outstanding of 154.97 million shares for fiscal year 2025.
  • BIO-TECHNE Corp showed a decrease of -2.1% in Shares Outstanding compared to the prior fiscal year.
  • All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.

Last verified:

Leave a Comment